Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Research & Development (2019 - 2026)

Enliven Therapeutics has reported Research & Development over the past 8 years, most recently at $20.7 million for Q1 2026.

  • Quarterly results put Research & Development at $20.7 million for Q1 2026, down 16.9% from a year ago — trailing twelve months through Mar 2026 was $81.6 million (down 4.73% YoY), and the annual figure for FY2025 was $85.9 million, up 6.29%.
  • Research & Development reached $20.7 million in Q1 2026 per ELVN's latest filing, down from $21.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $24.9 million in Q1 2025 and bottomed at $7.1 million in Q1 2022.
  • Median Research & Development over the past 5 years was $18.8 million (2024), compared with a mean of $16.6 million.
  • The largest annual shift saw Research & Development fell 24.7% in 2022 before it surged 150.43% in 2023.
  • Over 5 years, Research & Development stood at $8.2 million in 2022, then soared by 118.43% to $17.9 million in 2023, then grew by 15.74% to $20.7 million in 2024, then rose by 2.51% to $21.2 million in 2025, then fell by 2.63% to $20.7 million in 2026.
  • Business Quant data shows Research & Development for ELVN at $20.7 million in Q1 2026, $21.2 million in Q4 2025, and $18.2 million in Q3 2025.